Neurocrine starts Phase 1 trial for new obesity drug NBIP-'1968 targeting multiple metabolic pathways.

Rare endocrine and obesity drug acquisitions hit $12.9B; new MC4R therapies show promise but face tolerability challenges.

In the past four months, rare endocrine and obesity drug acquisitions totaled about $12.9 billion, highlighting strong investor interest. Rhythm Pharmaceuticals' IMCIVREE, an FDA-approved MC4R agonist for rare obesity disorders, generated $71.3 milli...